Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shandong Weigao Orthopaedic Device Co. Ltd. A stock ¥14.47, price ¥20.80, that is 30.4% below the price, quality 78 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥18.23 – ¥101.24 · fair‑value band ¥11.08 – ¥18.30 · the ¥20.80 price screens above the ¥14.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Shandong Weigao Orthopaedic Device Co. Ltd. A in your weekly email
Every Wednesday you see whether Shandong Weigao Orthopaedic Device Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments.
Show moreShow less
It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products include locking plate systems, intramedullary nail systems, hollow screw systems, and external fixation systems; and joint products, including hip joint prosthesis systems, knee joint prosthesis systems, and shoulder joint prosthesis systems.
In addition, the company sports medicine products comprise cruciate ligament reconstruction system, meniscus repair system, and sports trauma system; craniofacial surgery products; and orthopedic diagnostic equipment. The company was founded in 2005 and is based in Weihai, China.
Shandong Weigao Orthopaedic Device Co., Ltd. operates as a subsidiary of Shandong Weigao Group Medical Polymer Co., Limited.
Stock analysis
Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) currently trades at ¥20.80, while our model-based Fair Value estimate is ¥14.47, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥15.90 per share, and 1 of the 24 models we run sit above the ¥20.80 price.
Bear case: the Dividend Discount group reads lowest at ¥2.99, and 23 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥11.08 (bear) to ¥18.30 (bull), the price of ¥20.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Shandong Weigao Orthopaedic Device Co. Ltd. A reported revenue of 1.5B CNY in FY2025 versus 2.2B CNY in FY2021, a compound −8.3%/yr. Reported net income was 269M CNY in FY2025, compounding −21.0%/yr from FY2021.
Key figures
Market cap 8.3B CNY (≈ $1.2B) Small · P/E ratio 33.0 · P/S ratio 5.60 · EPS (TTM) ¥0.6300 · Dividend yield 1.6% · Net margin 17.4% · Return on equity 6.3% · Return on assets (EBIT) 7.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −30%, 688161 screens richer than that median.
Fair Value models
Bear¥11.08Fair Value ¥14.47Bull¥18.30
Price ¥20.80 · Downside -30.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2573 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.5%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 21%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +7.4% a year for the price.
Compare Shandong Weigao Orthopaedic Device Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score78 · Top 25%
Fair Value upside−30.4% · Below median
Profitability
Return on equity (12 months)6.3% · Above median
Return on assets5.3% · Above median
Net margin (12 months)17.4% · Top 25%
Operating margin (12 months)23.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−9.5% · Bottom 25%
Dividend yield (12 months)1.6% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)33.0× · Pricier than median
P/B2.01× · Pricier than median
P/S (12 months)5.60× · Priciest 25%
Price / free cash flow (fiscal year)21.4× · Cheaper than median
EV/EBITDA22.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 36
PAST (return on equity)25· sector 17
HEALTH (low debt)0· sector 98
DIVIDEND (yield)32· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Weigao Orthopaedic Device Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688161
Frequently asked questions
Is Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥14.47 versus a price of ¥20.80, about 30% lower (overvalued).
What is the fair value of 688161?
Our model-based fair value for Shandong Weigao Orthopaedic Device Co. Ltd. A is ¥14.47 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥20.80.
What is the quality score of 688161?
Shandong Weigao Orthopaedic Device Co. Ltd. A has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Our model-based price target is the fair value of ¥14.47 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario ¥11.08, optimistic scenario ¥18.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Weigao Orthopaedic Device Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥14.47, about 30% lower versus a price of ¥20.80 (overvalued). Cautious scenario ¥11.08, optimistic scenario ¥18.30. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Shandong Weigao Orthopaedic Device Co. Ltd. A reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Nov 6, 2026).
Does Shandong Weigao Orthopaedic Device Co. Ltd. A pay a dividend?
Shandong Weigao Orthopaedic Device Co. Ltd. A currently shows a dividend yield of 1.59% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) and when is the ex-dividend date?
Shandong Weigao Orthopaedic Device Co. Ltd. A pays a dividend of ¥0.33 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Oct 13, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 52.4% of earnings. Free cash flow covers the dividend 2.94 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
For today's price to be fair in a discounted-cash-flow model, Shandong Weigao Orthopaedic Device Co. Ltd. A would have to grow free cash flow by +9.2 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 688161 use?
Our models discount Shandong Weigao Orthopaedic Device Co. Ltd. A at 10.4 %: a base by market capitalisation (small), damped by beta 0.23, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shandong Weigao Orthopaedic Device Co. Ltd. A that is +9.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) delivered so far?
Over the past 5 years revenue at Shandong Weigao Orthopaedic Device Co. Ltd. A grew -3.5 % a year. The price currently implies free-cash-flow growth of +9.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shandong Weigao Orthopaedic Device Co. Ltd. A (+9.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The free-cash-flow yield on the price is 4.67 %: that much free cash flow Shandong Weigao Orthopaedic Device Co. Ltd. A produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Weigao Orthopaedic Device Co. Ltd. A it is ¥14.47 per share (as of Nov 6, 2026), against a price of ¥20.80. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shandong Weigao Orthopaedic Device Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 688161 trades above its calculated fair value: price ¥20.80, fair value ¥14.47, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688161?
No. The price is what the market pays today (¥20.80); the fair value is what the company's own numbers justify (¥14.47). For Shandong Weigao Orthopaedic Device Co. Ltd. A the two are ¥6.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Weigao Orthopaedic Device Co. Ltd. A worth?
The market values Shandong Weigao Orthopaedic Device Co. Ltd. A at about 8.3B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥20.80; our models calculate a fair value of ¥14.47 per share.
What do the bullish and bearish scenarios say about 688161?
Our models span a range for Shandong Weigao Orthopaedic Device Co. Ltd. A: cautious scenario ¥11.08, base ¥14.47, optimistic ¥18.30 per share (as of Nov 6, 2026, price ¥20.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688161?
Shandong Weigao Orthopaedic Device Co. Ltd. A trades at a price-to-earnings ratio of 33.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥14.47 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings, FY2025 ex one-offs: 41.7. Other multiples: P/B 2.0, P/S 5.6, EV/EBITDA 22.4.
How solid is the balance sheet of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Balance-sheet figures for Shandong Weigao Orthopaedic Device Co. Ltd. A (as of Nov 6, 2026): return on equity 6.3%. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is 688161 from its 52-week high?
Shandong Weigao Orthopaedic Device Co. Ltd. A trades at ¥20.80, about 34% below its 52-week high of ¥31.66 and 4% above the low of ¥20.07 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥14.47 is for.
Which stocks are comparable to Shandong Weigao Orthopaedic Device Co. Ltd. A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Weigao Orthopaedic Device Co. Ltd. A stock attractive at the current price?
The data as of Nov 6, 2026: price ¥20.80, calculated fair value ¥14.47 (−30%), Quality Score 78/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688161 calculated?
We run Shandong Weigao Orthopaedic Device Co. Ltd. A through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥14.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shandong Weigao Orthopaedic Device Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The closing price on Nov 6, 2026 was ¥20.80. Our model-based fair value is ¥14.47, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Weigao Orthopaedic Device Co. Ltd. A right now?
A high-quality business (quality 78/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (¥18.30). The favourable scenario is already priced in.
Key figures of Shandong Weigao Orthopaedic Device Co. Ltd. A
How large is the market capitalisation of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The market capitalisation of Shandong Weigao Orthopaedic Device Co. Ltd. A is 8.3B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The price-to-sales ratio of Shandong Weigao Orthopaedic Device Co. Ltd. A is 5.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Earnings per share at Shandong Weigao Orthopaedic Device Co. Ltd. A are ¥0.6300 (price ÷ EPS = P/E 33.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The dividend yield of Shandong Weigao Orthopaedic Device Co. Ltd. A is 1.6% (payout 52.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The net margin of Shandong Weigao Orthopaedic Device Co. Ltd. A is 17.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The return on equity (ROE) of Shandong Weigao Orthopaedic Device Co. Ltd. A is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
On an EBIT basis the return on assets of Shandong Weigao Orthopaedic Device Co. Ltd. A is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
The operating margin of Shandong Weigao Orthopaedic Device Co. Ltd. A is 23.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Revenue at Shandong Weigao Orthopaedic Device Co. Ltd. A is growing −9.5% versus a year earlier (3y avg −9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Weigao Orthopaedic Device Co. Ltd. A (688161)?
Earnings per share at Shandong Weigao Orthopaedic Device Co. Ltd. A are growing +0.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Shandong Weigao Orthopaedic Device Co. Ltd. A in the live analysis
One click puts Shandong Weigao Orthopaedic Device Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026